Key facts
- Saba Capital Management, L.P. filed SCHEDULE 13D/A for abrdn Life Sciences Investors Common Shares, $0.01 par value (HQL).
- Disclosed ownership: 5%.
- Date of event: 19 Feb 2026.
Saba Capital Management, L.P. - 19 Feb 2026 SCHEDULE 13D/A Report for abrdn Life Sciences Investors Common Shares, $0.01 par value (HQL)
- Filing Manager
- Saba Capital Management, L.P.
- Reporting Manager
- Saba Capital Management, L.P.
- Symbol
- HQL
- Shares outstanding
- 29,579,010 shares
- Disclosed Ownership
- 1,464,161 shares
- Ownership
- 5%
- Form type
- SCHEDULE 13D/A
- Filing time
- 23 Feb 2026, 17:50:06 UTC
- Date of event
- 19 Feb 2026
- Previous filing
- 11 Feb 2026
- SEC
- View on sec.gov
Key filing fact
Saba Capital Management, L.P. disclosed 5% ownership in abrdn Life Sciences Investors Common Shares, $0.01 par value (HQL) on 19 Feb 2026.
Change
- Previous schedule filing date: 11 Feb 2026.
- Current filing was accepted on 23 Feb 2026, 17:50.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (3)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Saba Capital Management, L.P. | 5% | 1,464,161 | 0 | 1,464,161 | /s/ Michael D'Angelo | General Counsel | 0001510281 |
| Boaz R. Weinstein | 5% | 1,464,161 | 0 | 1,464,161 | /s/ Michael D'Angelo | Authorized Signatory | 0001608233 |
| Saba Capital Management GP, LLC | 5% | 1,464,161 | 0 | 1,464,161 | /s/ Michael D'Angelo | Attorney-in-fact* |
CIK / CUSIP context first